Aquestive Therapeutics Inc
Aquestive Therapeutics Inc (AQST) Historical Volatility
AQST's 30 day historical volatility is 63.17%, in the 74th percentile of readings over the past year. This is a high percentile, meaning Aquestive Therapeutics Inc shares have swung far more than usual. AQST's 30 day implied volatility sits at 55.33%, with an IV Rank of 2.78%, leaving IV 7.84 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 19, 2026.
Read more
Tracking AQST historical volatility helps you see how much Aquestive Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, AQST's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor AQST 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. AQST's 30 day historical volatility, or AQST HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing AQST's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 19, 2026
As of Nov 19, 2026
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →